Replies to post #587033 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Helping.

[flipper44]

There it is again. Automated product release “needed for scale up.”

I take that as code for prerequisite, maybe I’m wrong, but when she discussed it two months prior to that February statement, at the Dec 21 ASM, she said they’d been working on it for more than three years, and some things can take three years. They weren’t “ready” to make an announcement yet at the ASM.

We are now likely over 3.5 years. You’d think, you’d think they’d be done.

[ATLnsider]

Thanks for that reminder sentiment_stocks. I also like the message in the next paragraph which specifically states that NWBio has been in talks with Charles River Laboratories (CRL, fka Cognate) to resume manufacturing of DCVax-L in the US:

In the US, the Company entered into contract discussions for resumption of manufacturing capacity there.

I have been buying more NWBO shares all week, and I will continue buying and accumulating more shares at these low prices.

As we know, for CRL to commit to, or agree to resume manufacturing of DCVax-L, it will require NWBio to make a financial commitment to reserve dedicated clean rooms at the Memphis facility.

NWBio would not agree to make this contractually obligated financial commitment unless they have received some positive feedback from the FDA & Health Canada about the likelihood of DCVax-L being approved.